Fosun Pharma’s New Drug Application Accepted

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary’s new drug, Dobutamine Hydrochloride Injection, aimed at enhancing myocardial contractility and for use in stress echocardiography, has been accepted for registration by the National Medical Products Administration. The company has invested about RMB 3.96 million in the drug’s development, with the market for the drug’s active ingredient reaching sales of RMB 498 million in China in 2023.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.